Comparison of papanicolaou smear and human papillomavirus (HPV) test as cervical screening tools: can we rely on HPV test alone as a screening method? An 11-year retrospective experience at a single institution
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The decrease in incidence of cervical dysplasia and carcinoma has not been as dramatic as expected with the development of improved research tools and test methods. The human papillomavirus (HPV) test alone has been suggested for screening in some countries. The National Cancer Screening Project in Korea has applied Papanicolaou smears (Pap smears) as the screening method for cervical dysplasia and carcinoma. We evaluated the value of Pap smear and HPV testing as diagnostic screening tools in a single institution. Methods: Patients co-tested with HPV test and Pap smear simultaneously or within one month of each other were included in this study. Patients with only punch biopsy results were excluded because of sampling errors. A total of 999 cases were included, and the collected reports encompassed results of smear cytology, HPV subtypes, and histologic examinations. Results: Sensitivity and specificity of detecting high-grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma (SCC) were higher for Pap smears than for HPV tests (sensitivity, 97.14%; specificity, 85.58% for Pap smears; sensitivity, 88.32%; specificity, 54.92% for HPV tests). HPV tests and Pap smears did not differ greatly in detection of low-grade squamous intraepithelial lesion (85.35% for HPV test, 80.31% for Pap smears). When atypical glandular cells were noted on Pap smears, the likelihood for histologic diagnosis of adenocarcinoma following Pap smear was higher than that of high-risk HPV test results (18.8 and 1.53, respectively). Conclusions: Pap smears were more useful than HPV tests in the diagnosis of HSIL, SCC, and glandular lesions.
Abstract
Background: The decrease in incidence of cervical dysplasia and carcinoma has not been as dramatic as expected with the development of improved research tools and test methods. The human papillomavirus (HPV) test alone has been suggested for screening in some countries. The National Cancer Screening Project in Korea has applied Papanicolaou smears (Pap smears) as the screening method for cervical dysplasia and carcinoma. We evaluated the value of Pap smear and HPV testing as diagnostic screening tools in a single institution. Methods: Patients co-tested with HPV test and Pap smear simultaneously or within one month of each other were included in this study. Patients with only punch biopsy results were excluded because of sampling errors. A total of 999 cases were included, and the collected reports encompassed results of smear cytology, HPV subtypes, and histologic examinations. Results: Sensitivity and specificity of detecting high-grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma (SCC) were higher for Pap smears than for HPV tests (sensitivity, 97.14%; specificity, 85.58% for Pap smears; sensitivity, 88.32%; specificity, 54.92% for HPV tests). HPV tests and Pap smears did not differ greatly in detection of low-grade squamous intraepithelial lesion (85.35% for HPV test, 80.31% for Pap smears). When atypical glandular cells were noted on Pap smears, the likelihood for histologic diagnosis of adenocarcinoma following Pap smear was higher than that of high-risk HPV test results (18.8 and 1.53, respectively). Conclusions: Pap smears were more useful than HPV tests in the diagnosis of HSIL, SCC, and glandular lesions.
참고문헌 (29)
- Snijders PJ, "HPV-mediated cervical carcinogenesis : concepts and clinical implications", J Pathol, 208, pp.152~164 (2006)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Kim Y, "Overview of the National Cancer screening programme and the cancer screening status in Korea", Asian Pac J Cancer Prev, 12, pp.725~730 (2011)
- Polman NJ, "HPVbased cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme", Prev Med, 119, pp.108~117 (2019)
- Sangrajrang S, "Comparative accuracy of Pap smear and HPV screening in Ubon Ratchathani in Thailand", Papillomavirus Res, 3, pp.30~35 (2017)
- Ronco G, "Efficacy of HPV-based screening for prevention of invasive cervical cancer : follow-up of four European randomised controlled trials", Lancet, 383, pp.524~532 (2014)
- Tota JE, "Introduction of molecular HPV testing as the primary technology in cervical cancer screening : acting on evidence to change the current paradigm", Prev Med, 98, pp.5~14 (2017)
- US Preventive Services Task Force, "Screening for cervical cancer : US Preventive Services Task Force recommendation statement", JAMA, 320, pp.674~686 (2018)
- Nayar R, "The Bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes" (2015), Springer
- Brown LD, "Interval estimation for a binomial proportion", Stat Sci, 16, pp.101~133 (2001)
- Fleiss JL, "Statistical methods for rates and proportions" (1981), John Wiley
- Tracht J, "Primary HPV testing verification : a retrospective ad-hoc analysis of screening algorithms on women doubly tested for cytology and HPV", Diagn Cytopathol, 45, pp.580~586 (2017)
- Costa S, "The predictive value of human papillomavirus testing for the outcome of patients conservatively treated for stage IA squamous cell cervical carcinoma", J Clin Virol, 70, pp.53~57 (2015)
- McKenna M, "Human papillomavirus testing in young women : clinical outcomes of human papillomavirus triage in a UK cervical screening program", Cancer Cytopathol, 122, pp.702~710 (2014)
- Pileggi C, "Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta-analysis of randomized controlled trials", Int J Cancer, 135, pp.166~177 (2014)
- Garland SM, "Impact and effectiveness of the quadrivalent human papillomavirus vaccine : a systematic review of 10 years of real-world experience", Clin Infect Dis, 63, pp.519~527 (2016)
- 심승혁, "Nationwide cervical cancer screening in Korea: data from the National Health Insurance Service Cancer Screening Program and National Cancer Screening Program, 2009–2014", Journal of Gynecologic Oncology, 28(5), pp.1~12 (2017), 대한부인종양학회[DOI]
- Sherman ME, "Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3 : dominant impact of surrounding lowgrade lesions", Cancer Epidemiol Biomarkers Prev, 12, pp.1038~1044 (2003)
- Jastania R, "Characteristics of apparently false-negative digene hybrid capture 2 high-risk HPV DNA testing", Am J Clin Pathol, 125, pp.223~228 (2006)
- Cancer Genome Atlas Research Network, "Integrated genomic and molecular characterization of cervical cancer", Nature, 543, pp.378~384 (2017)
- Stolnicu S, "International Endocervical Adenocarcinoma Criteria and Classification(IECC) : a new pathogenetic classification for invasive adenocarcinomas of the endocervix", Am J Surg Pathol, 42, pp.214~226 (2018)
- Hodgson A, "International endocervical adenocarcinoma criteria and classification : validation and interobserver reproducibility", Am J Surg Pathol, 43, pp.75~83 (2019)
- Kurman RJ, "WHO classification of tumours of female reproductive organs" (2014), IARC Press
- Nasser H, "Eleven-year review of data on Pap smears in Saudi Arabia: we need more focus on glandular abnormalities!", Ann Saudi Med, 37, pp.265~271 (2017)
- Patanwala IY, "A systematic review of randomized trials assessing human papillomavirus testing in cervical acancer screening", Am J Obstet Gynecol, 208, pp.343~353 (2013)
- Kitchener HC, "HPV testing in combination with liquid-based cytology in primary cervical screening(ARTISTIC) : a randomised controlled trial", Lancet Oncol, 10, pp.672~682 (2009)
- Luyten A, "Early detection of CIN3 and cervical cancer during long-term follow-up using HPV", Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme, 2014, pp.135, 1408~1416
- Sasagawa T, "Immune responses against human papillomavirus(HPV)infection and evasion of host defense in cervical cancer", J Infect Chemother, 18, pp.807~815 (2012)